Glenmark Pharmaceuticals Limited (GLENMARK.BO)
INR 1541.0
(1.1%)
INR 1541.0
(1.1%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 65.11 Billion INR | -31.7% |
| 2022 | 95.32 Billion INR | 24.69% |
| 2021 | 76.45 Billion INR | -10.47% |
| 2020 | 85.39 Billion INR | -0.88% |
| 2019 | 86.14 Billion INR | 12.01% |
| 2018 | 76.9 Billion INR | 3.48% |
| 2017 | 74.32 Billion INR | 2.19% |
| 2016 | 72.72 Billion INR | 10.77% |
| 2015 | 65.66 Billion INR | -1.81% |
| 2014 | 66.87 Billion INR | 18.63% |
| 2013 | 56.37 Billion INR | 28.59% |
| 2012 | 43.83 Billion INR | 26.81% |
| 2011 | 34.56 Billion INR | 13.94% |
| 2010 | 30.33 Billion INR | 20.61% |
| 2009 | 25.15 Billion INR | -5.29% |
| 2008 | 26.56 Billion INR | 86.24% |
| 2007 | 14.26 Billion INR | 13.42% |
| 2006 | 12.57 Billion INR | 31.24% |
| 2005 | 9.58 Billion INR | 62.86% |
| 2004 | 5.88 Billion INR | 166.28% |
| 2003 | 2.2 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -78.47 Billion INR | -220.53% |
| 2023 FY | 65.11 Billion INR | -31.7% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 102.7 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 65.11 Billion INR | 0.0% |
| 2022 Q4 | 95.32 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 95.32 Billion INR | 24.69% |
| 2022 Q2 | 80.91 Billion INR | 0.0% |
| 2021 Q4 | 76.45 Billion INR | 0.0% |
| 2021 FY | 76.45 Billion INR | -10.47% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 76.13 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 FY | 85.39 Billion INR | -0.88% |
| 2020 Q4 | 85.39 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 85.97 Billion INR | 0.0% |
| 2019 Q2 | 79.39 Billion INR | 0.0% |
| 2019 Q4 | 86.14 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 86.14 Billion INR | 12.01% |
| 2018 Q2 | 81.35 Billion INR | 0.0% |
| 2018 FY | 76.9 Billion INR | 3.48% |
| 2018 Q4 | 76.9 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q2 | 75.62 Billion INR | 0.0% |
| 2017 Q4 | 74.32 Billion INR | 0.0% |
| 2017 FY | 74.32 Billion INR | 2.19% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 85.12 Billion INR | 0.0% |
| 2016 Q4 | 72.72 Billion INR | 0.0% |
| 2016 FY | 72.72 Billion INR | 10.77% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q4 | 65.66 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 65.66 Billion INR | -1.81% |
| 2015 Q2 | 63.57 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q2 | 54.1 Billion INR | 0.0% |
| 2014 Q4 | 66.87 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 FY | 66.87 Billion INR | 18.63% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 56.37 Billion INR | 28.59% |
| 2013 Q4 | 56.37 Billion INR | 0.0% |
| 2013 Q2 | 52.22 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q4 | 43.83 Billion INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 FY | 43.83 Billion INR | 26.81% |
| 2011 FY | 34.56 Billion INR | 13.94% |
| 2011 Q4 | 34.56 Billion INR | 0.0% |
| 2010 FY | 30.33 Billion INR | 20.61% |
| 2009 FY | 25.15 Billion INR | -5.29% |
| 2008 FY | 26.56 Billion INR | 86.24% |
| 2007 FY | 14.26 Billion INR | 13.42% |
| 2006 FY | 12.57 Billion INR | 31.24% |
| 2005 FY | 9.58 Billion INR | 62.86% |
| 2004 FY | 5.88 Billion INR | 166.28% |
| 2003 FY | 2.2 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Ajanta Pharma Limited | 10.71 Billion INR | -507.927% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -8206.81% |
| Sigachi Industries Limited | 2.53 Billion INR | -2472.262% |
| Bal Pharma Limited | 2.51 Billion INR | -2492.737% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -2743.934% |
| Medico Remedies Limited | 438.24 Million INR | -14757.196% |
| Lasa Supergenerics Limited | 541.92 Million INR | -11914.72% |
| Venus Remedies Limited | 1.39 Billion INR | -4574.811% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -1572.552% |
| Alpa Laboratories Limited | 307.12 Million INR | -21100.295% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -480.409% |
| Shilpa Medicare Limited | 12.93 Billion INR | -403.467% |
| Aarti Drugs Limited | 11.5 Billion INR | -465.984% |
| Lupin Limited | 96.23 Billion INR | 32.344% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 57.222% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 9.306% |
| Windlas Biotech Limited | 1.76 Billion INR | -3593.809% |
| Suven Life Sciences Limited | 148.62 Million INR | -43709.939% |
| Eris Lifesciences Limited | 38.26 Billion INR | -70.144% |
| Valiant Laboratories Limited | 1.05 Billion INR | -6052.631% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -508.057% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -360.348% |
| Ipca Laboratories Limited | 33.74 Billion INR | -92.962% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -2987.5% |
| Achyut Healthcare Limited | 2.01 Million INR | -3234414.158% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 64.531% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -1237.617% |
| RPG Life Sciences Limited | 1.38 Billion INR | -4617.488% |
| Mankind Pharma Limited | 23.87 Billion INR | -172.719% |
| Laurus Labs Limited | 42.71 Billion INR | -52.432% |
| Piramal Pharma Limited | 74 Billion INR | 12.018% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -5487.895% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 20.645% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -300.096% |
| Unichem Laboratories Limited | 8.06 Billion INR | -706.9% |
| Sequent Scientific Limited | 8.27 Billion INR | -686.908% |
| Novartis India Limited | 1.8 Billion INR | -3515.056% |
| Wanbury Limited | 3.15 Billion INR | -1963.395% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -3100.759% |
| Wockhardt Limited | 39.87 Billion INR | -63.308% |
| Themis Medicare Limited | 1.88 Billion INR | -3349.557% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -21840.548% |
| Jubilant Pharmova Limited | 61.27 Billion INR | -6.262% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -1156.746% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 39.131% |
| Divi's Laboratories Limited | 18.99 Billion INR | -242.869% |
| NATCO Pharma Limited | 10.53 Billion INR | -518.218% |
| Gufic Biosciences Limited | 5.59 Billion INR | -1062.732% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -928.785% |
| Ind-Swift Limited | 13.45 Billion INR | -383.988% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -2442.198% |
| FDC Limited | 3.7 Billion INR | -1655.382% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -2089.397% |
| Granules India Limited | 22.95 Billion INR | -183.653% |
| Medicamen Biotech Limited | 940.36 Million INR | -6823.974% |
| Alkem Laboratories Limited | 48.6 Billion INR | -33.959% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -1678.444% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -22445.359% |
| Brooks Laboratories Limited | 248.6 Million INR | -26090.872% |
| Megasoft Limited | 1.85 Billion INR | -3413.532% |
| ZIM Laboratories Limited | 2.08 Billion INR | -3029.179% |
| Strides Pharma Science Limited | 37.68 Billion INR | -72.797% |
| Neuland Laboratories Limited | 5.49 Billion INR | -1084.142% |
| Morepen Laboratories Limited | 4.45 Billion INR | -1359.952% |
| Hikal Limited | 12.99 Billion INR | -401.049% |
| Indoco Remedies Limited | 10.34 Billion INR | -529.558% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -689.154% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -10012.205% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -3194.561% |
| Hester Biosciences Limited | 3.59 Billion INR | -1711.289% |